Anti-Mouse CD19 [Clone 1D3] - PE
Referencia C2107-50
embalaje : 50ug
Marca : Leinco Technologies
Contact local distributor :
Teléfono : +1 850 650 7790
AntiMouse CD19 [Clone 1D3] — PE
AntiMouse CD19 [Clone 1D3] — PE
Product No.: C2107
Clone 1D3 Target CD19 Formats AvailableView All Product Type Monoclonal Antibody Isotype IgG2a Applications FC |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Immunogen Fusion of NS1 Myeloma cells with spleen cells Product Concentration 0.2 mg/ml Formulation This Rphycoerythrin (RPE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This Rphycoerythrin (RPE) conjugate is stable when stored at 28°C. Do not freeze. Country of Origin USA Shipping Next Day 28°C Excitation Laser Blue Laser (488 nm) and/or Green Laser (532 nm)/YellowGreen Laser (561 nm) RRIDAB_2829189 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this 1D3 antibody for staining cells in flow cytometry is ≤ ≤0.125 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Reported Applications For Relevant Conjugates ? B IP For specific conjugates of this clone, review literature for suggested application details. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone 1D3 recognizes an epitope on mouse CD19. Background CD19 is a 95 kD transmembrane glycoprotein and member of the Ig superfamily. The antigen serves as an adaptor protein; drawing cytoplasmic signaling proteins to the membrane. It works via the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Because of its presence on all B cells, CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for the immunotherapy of lymphoproliferative disorders. Emerging studies indicate that CD19 plays an active role in fueling the growth of these cancers, most notably by stabilizing the concentrations of the MYC oncoprotein, making CD19 an attractive therapeutic target with respect to its downstream signaling. Antigen Distribution CD19 is expressed in the majority of ProB cells to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19. Ligand/Receptor CD21, CD81, Leu13. PubMed NCBI Gene Bank ID UniProt.org Research Area Immunology References & Citations |